Table 2 Anti-cN-1A reactivity in sera from patients with sporadic inclusion body myositis (sIBM) and in healthy controls as determined by anti-cN-1A IgG ELISA at the Institute for Experimental Immunology (Lübeck, Germany)
Cohorts | n | Anti-cN-1A ELISA (IgG) | |||
|---|---|---|---|---|---|
Positive | Negative | Sensitivity (CI 95%) | Specificity (CI 95%) | ||
sIBM | 51 | 20 | 31 | 39.2% (27.0–52.9%) |  |
Healthy controls | 202 | 7 | 195 |  | 96.5% (92.9–98.5%) |